Frontlight ResearchEarly access
TerminatedPhase 1
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Key facts
- Who runs it
- TG Therapeutics, Inc.
- Where
- Chattanooga, Fayetteville, Hackensack, Houston, and Nashville, United StatesSee the 5 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 21 people enrolled
- Started
- 28 Apr 2021
- Ended
- 12 Jun 2024
- Type of study
- Interventional, 3 groups
- Treatments tested
- TG-1801
- Ublituximab
- Record updated
- 31 July 2024
- Why it stopped
- Strategic/Business Decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- B-cell non-Hodgkin lymphoma (NHL) including Richter's Transformation (RT) and transformed follicular lymphoma (FL), that warrants systemic therapy
- Chronic Lymphocytic Leukemia (CLL), that warrants systemic therapy as defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) (Hallek 2018)
- Treatment Status:; NHL subjects: relapsed to or refractory after at least two prior standard systemic therapies (excluding antibiotics); RT subjects: relapsed or refractory after at least two prior lines of therapy for CLL/ Small lymphocytic lymphoma (SLL) or RT; CLL subjects: relapsed to or refractory after at least two prior standard therapies
- Measurable disease defined as:; NHL (including SLL): at least 1 measurable disease lesion > 1.5 centimeters (cm); CLL: at least 1 measurable disease lesion
Who cannot take part
- Prior therapy with any agent blocking the CD47/SIRPα pathway or any previous CD19 targeting therapy,
- Subjects receiving cancer therapy (i.e. chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) or any investigational drug within 21 days of Cycle 1 Day 1
- Prior autologous stem cell transplant (SCT) within 6 months
Where in United States
- Chattanooga, TennesseeHospital not named in the registry
- Fayetteville, ArkansasHospital not named in the registry
- Hackensack, New JerseyHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
About the trial
What the trial wants to find out
The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.
The 3 groups in the trial
- Cohort A: TG-1801Treatment being tested
TG-1801 Single Agent As per protocol v3.0, Cohort A is no longer enrolling.
Treatment: TG-1801
- Cohort B: TG-1801Treatment being tested
TG-1801 Single Agent, escalating doses
Treatment: TG-1801
- Cohort C: TG-1801 + UblituximabTreatment being tested
TG-1801 in combination with ublituximab As per protocol v3.0, ublituximab will be discontinued and the Cohort C is no longer enrolling.
Treatment: TG-1801 and Ublituximab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Record updated
- 31 July 2024